Lupin (LUPIN) — Announcement

📢 Key Event
Lupin completes 82.2% stake acquisition in Kaveri Therapeutics via oncology program licensing deal

🔄 What Changed
82.2% equity stake acquired in newly formed Kaveri Therapeutics; USD 1.6 million valuation of licensed programs

💡 Investor Takeaway
Lupin is spinning out its oncology programs to focus on core businesses while leveraging Kaveri's leadership for accelerated development.

Lupin announced the completion of its acquisition of an 82.2% stake in newly formed Kaveri Therapeutics Inc. through a licensing deal for two oncology programs, valued at USD 1.6 million, effective July 20, 2026. The transaction marks Lupin's strategic exit from direct development of LNP7457 and LNP8701 to accelerate their advancement under Kaveri's leadership.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How will Lupin's core business segments be impacted by exiting oncology development?" "What valuation multiples are implied for Lupin's USD 1.6 million consideration?" "How does Kaveri's leadership team plan to fund clinical trials beyond Lupin's seed investment?"

Ask AI Free →

📊 More LUPIN filings

See all LUPIN filings →

🔥 Also filed on 21 July 2026

AARTIIND Aarti Industries Limited Financial Results ANTHEM Anthem Biosciences Limited Financial Results MUFIN Mufin Green Finance Limited Corporate Action ABCAPITAL Aditya Birla Capital Limited Announcement CYIENTDLM Cyient DLM Limited Financial Results KIOCL KIOCL Limited Insider Trading

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.